Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
49.37
-2.98 (-5.69%)
At close: May 30, 2025, 4:00 PM
49.95
+0.58 (1.17%)
After-hours: May 30, 2025, 7:59 PM EDT
Sanofi Revenue
Sanofi had revenue of 10.61B EUR in the quarter ending March 31, 2025, a decrease of -4.61%. This brings the company's revenue in the last twelve months to 45.17B, down -2.42% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.17B EUR
Revenue Growth
-2.42%
P/S Ratio
2.48
Revenue / Employee
544,970 EUR
Employees
82,878
Market Cap
120.98B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
SNY News
- 18 hours ago - Sanofi: Finding Value In The Wake Of Itepekimab's Disappointment - Seeking Alpha
- 1 day ago - Itepekimab Failure A Setback For Sanofi And Regeneron - Seeking Alpha
- 2 days ago - Sanofi, Regeneron's Itepekimab Delivers Mixed Results in Late-Stage Trials - WSJ
- 2 days ago - Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs - GlobeNewsWire
- 4 days ago - US FDA approves use of Sanofi's meningococcal vaccine in infants - Reuters
- 5 days ago - C4X Discovery receives latest milestone payment from Sanofi - GlobeNewsWire
- 5 days ago - Sanofi, VNVC launch vaccine factory in Vietnam - Reuters
- 5 days ago - Press Release: Sanofi completes acquisition of DR-0201 - GlobeNewsWire